|
Overview: This course will review the company Master Validation Plan for major key inputs and CGMP deficiencies. It will address the FDA's newer and tougher regulatory stance. This course's aim is to prove "Product Risk Based V&V" by sufficient, targeted and documented risk-based V&V test case elements/scripts. It will teach participants to evaluate its elements against ISO 14971 and ICH Q9 for hazard analysis and product risk management. This course will evaluate different field-tested, U.S. FDA-reviewed V&V protocols; how to employ equipment/process Requirements Specs / DQs, IQs, OQs, and PQs, or their equivalents per ASTM E2500, all against a background of limited company resources. It will review a matrix that simplifies "as-product", in-product", process and equipment, et al, software VT&V, to assure key FDA requirements are not overlooked. While considering the QMS and 21 CFR Part 11; this course will make practical application of these same in two hands-on sessions. Why you should attend: This session helps participants: • Understand Verification and Validation, differences and how they work together; • Discuss recent regulatory expectations; • Know how to document a "risk-based" rationale, and use it in a resource-constrained environment; • Determine key "milestones" and "tasks" in a project; • Locate and document key subject "inputs"; • Compile "generic" Master and Individual Validation Plans; • Learn the key element of a Product V&V File/Protocol; • Understand how to develop Process and/or Production/Test Equipment V&V Files/Protocols; • Get a grasp of basic Test Case construction; • Understand sample sizes and their justification; • Learn the key elements of Software V&V expected by the FDA and how to document; • Deal with hardware and software vendors, sales and marketing • Consider a field-tested software V&V documentation "model"; • See how to compile QMS Electronic Records and Electronic Signatures V&Vs to satisfy 21 CFR Part 11. Who Will Benefit: This workshop will provide valuable assistance to all regulated companies that need to review and modify their Master Validation Planning and V&V activities / plan(s). This information addresses Medical Devices, Pharmaceutical, Diagnostic, and Biologics requirements and implementation. The employees who will benefit include: • Senior and middle management and staff • Regulatory Affairs • Quality Assurance or Quality Control Professionals • QA/QC • IT/IS • R&D • Production Management • Manufacturing Engineers • Process Engineers • Software Engineers • Project Managers • Hardware and software vendors, sales and marketing • Any professional tasked with V&V responsibilities Course Outline: Day One: Lecture 1: Master Validation Planning and the Master Validation Plan(s) Lecture 2: Product, Process / Equipment Hardware V&V Lecture 3: Product / Device V&V Lecture 4: Software V&V Lecture 5: Quality Management System / 21 CFR Part 11 V&V Lecture 6: Summary of morning discussion Lecture 7: Group activity on the MVPs Lecture 8: Review of group activity and Q&A Day Two: Lecture 9: Software V&V documentation "model" Lecture 10: Software V&V protocols - "black box", "white box" Lecture 11: Electronic Records and Electronic Signatures (Part 11) Lecture 12: Summary of morning discussion Lecture 13: Group activity on 1) hardware / equipment, and 2) software V&V protocols Lecture 14: Review of group activity and Q&A Lecture 15: Course summary discussion Lecture 16: Summary of morning discussion Lecture 17: Group activity on the MVPs Lecture 18: Review of group activity and Q&A About Speaker – John E Lincoln is Principal of J. E. Lincoln and Associates LLC, a consulting company. John, a graduate of UCLA, is a medical device and Regulatory Affairs consultant. He has helped companies to implement or modify their GMP systems and procedures, product risk management and U.S. FDA responses. In addition, he has successfully designed, written and run all types of process, equipment and software qualifications/validations, which have passed FDA audit or submission scrutiny, and have been described in peer-reviewed technical articles and workshops worldwide. John has also managed pilot production, regulatory affairs, product development/design control, 510(k) submissions and risk management per ISO 14971 and implemented projects. With over 28 years of experience in the FDA-regulated medical products industry, he has worked from start-ups to Fortune 100 companies, including Abbott Laboratories, Hospira, and Tyco/Mallinckrodt. Date, Venue & Price: Location: Las Vegas NV March 27th & 28th, 2014 9 AM to 6 PM Venue: Hilton Grand Vacations Suites at the Flamingo Price: $1,295.00 Register now and save $200. (Early Bird) Until January 15, Early Bird Price: $1,295.00 From January 16 to March 25, Regular Price: $1,495.00 Address: 3575 Las Vegas Boulevard South, Las Vegas, Nevada, 89109-4313, USA Contact Information: Event Coordinator Toll free: 1800 447 9407 Fax: 302 288 6884 Email: support@globalcompliancepanel.com Website: https://www.globalcompliancepanel.com LIVE CHAT SUPPORT - http://www.globalcompliancepanel.com/chat/client.php Event Link - http://bit.ly/1g7dx3G GlobalCompliancePanel NetZealous LLC 161 Mission Falls Lane, Suite 216, Fremont, CA 94539, USA.
Related Articles -
Software Validation, FDA Inspections, HIPAA Compliance, 21 CFR Part11, Computer System Validation, Hazard Analysis, Verification vs. Validation,
| 
